nolateral joint involvement, which have been reported to be very low in the overall literature (5–7). Another unusual feature in our case history was the dramatic clinical picture. The absence of a skin rash, on the contrary, cannot be considered an unexpected finding, since its prevalence in a pediatric population with B19-associated arthritis has been recently reported to be lower than 50% (5).

In this case the overall clinical picture, the laboratory tests demonstrating abnormal indices of inflammation and the rapid response to anti-inflammatory therapy could suggest the hypothesis of a rheumatic-like disease. It is known that both in children and adults B19 infection has been implicated as a possible triggering factor of autoimmune diseases affecting the joints, connective tissue and large and small vessels, thus confirming that B19 may contribute to the induction of autoimmune reactions (8, 9).

Therefore, we can underline, on the basis of our atypical case report, the conclusions by Oguz et al. (5) that B19 IgM have to be searched for in children who present with acute monarthritides, whatever the clinical picture and localization.

C. RUGGERI, MD
M. WASNIEWSKA, MD PhD
G. CRISAFULLI, MD
F. DE LUCA, MD
Department of Pediatrics, University of Messina, Italy.

Corresponding author: Dott.ssa Caterina Ruggeri, Dipartimento di Science Pediatriche Mediche e Chirurgiche, Policlinico Universitario, Viale Gazzi, 98100 Messina, Italy. E-mail: wasniewska@yahoo.it

References


Comparison of serum IgE levels between female and male SLE patients, with reference to gender differences in the incidence of SLE

Sir,

Several studies have been performed to investigate the importance of the serum IgE level in systemic lupus erythematosus (SLE) (1-3). It has been reported that serum IgE levels are significantly higher in the active stage of SLE when compared with the level during remission (1). Our recent study of 51 patients with SLE (45 women and 6 men) revealed significantly higher IgE levels in SLE patients compared with normal controls (450.5 ± 1136 IU/ml in 51 SLE patients vs. 72.7 ± 87 IU/ml in 391 controls, p = 0.007) independent of disease activity (2). In general, the IgE level in SLE patients does not appear to be related to the development of atopic diseases (3).

As shown in Table I, 7 out of 12 male patients (58%) in our SLE cohort showed high serum IgE levels (> 250 IU/ml) compared with normal controls (normal ≤ 250 IU/ml). In contrast, 21% (10/47) of our female SLE patients showed high IgE levels (> 250 IU/ml). There was a significant difference in the prevalence of high serum IgE levels between male and female SLE patients (p = 0.011 by the chi-squared test performed with SPSS software; Chicago, USA).

In contrast, a significant difference was not observed in the average amounts of IgE levels between male and female SLE patients (399 ± 372 IU/ml in 12 male patients vs. 330 ± 755 IU/ml in 47 female patients, p = 0.66), probably because certain female patients showed extremely high levels of IgE. In our study, no significant correlation was observed between IgE and other serum parameters such as immunoglobulins (IgG, IgA, and IgM) and autoantibodies. Thus, their high serum levels of IgE did not seem to result from polyclonal B cell activation. A history of atopic disease in 12 male patients was only obtained in one patient.

The prevalence of SLE is significantly higher in females than in males, and this is probably due to promotion of the immune response by sex hormones (especially estrogen), including the production of several cytokines (such as interleukin (IL)-1, -6, and -10) and antibodies mediated by these T helper-2 (Th-2) cytokines (4). Estrogens are also reported to contribute to an increase in the transcription of autoantigens (5), such as human endogenous retroviruses (HERV) that may be a plausible causative agent of SLE (6). Thus, female hormones such as estrogen appear to cause a decrease in the threshold for responsiveness to autoantigens and/or production of autoantigens, and that this is related to a higher incidence of SLE in females. In addition, DNAmethylation seems to play an important role in the induction of autoimmunity in SLE. Low levels of cytosine methylation (indicated by low activity of DNA methyltransferase-1 (DNMT-1), a methylation-regulating enzyme) in the regulatory sequences of DNA leads to transcriptional activation of genes, and DNA methylation is decreased in both male and female SLE patients (7). DNAhypomethylation (implied by low DNMT-1 activity) is thought to contribute to hyperresponsiveness to autoantigens in SLE patients and to the production of autoantigens, including HERV (7). It has been reported that IgE production is contributed by DNA hypomethylation and is also enhanced by estrogens (8, 9). The levels of IgE production mediated by IL-4 are known to be closely associated with the estrogen level (4). Thus, high IgE levels in male SLE patients may reflect stronger hyperresponsiveness due to DNAhypomethylation that is not related to the influence of sex hormones.

Further precise clinical and/or laboratory investigations of male SLE, as well as female patients with the postmenopausal onset of SLE (10), may make an important contribution to elucidation of the reason for the gender bias of this disease.

I. SEKIGAWA1 M. YAMADA1 H. OGAWA3
N. IIDA1

Table I. Serum IgE levels in male and female SLE patients.

<table>
<thead>
<tr>
<th>Sex</th>
<th>No. of pts.</th>
<th>High (&gt; 250 IU/ml)</th>
<th>Low (≤ 250 IU/ml)</th>
<th>P value (male vs. female)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>12</td>
<td>7 (58%)</td>
<td>5 (42%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Female</td>
<td>47</td>
<td>10 (21%)</td>
<td>37 (79%)</td>
<td></td>
</tr>
</tbody>
</table>

IgE was measured by chemiluminescent enzyme immunoassay (CLEIA; Fuji Levio Co., Inc. Tokyo, Japan).
Letters to the Editor

IV INTERNATIONAL CONFERENCE ON SEX HORMONES, PREGNANCY & THE RHEUMATOID DISEASES
Stresa, Italy, 20-22 September 2004

Topics: Physiology and pathology of placental and fetal development; autoimmunity as a cause of pregnancy loss; counselling for patients; pregnancy, neonatal outcome; drugs in pregnancy; long-term outcome of children born to patients with rheumatic disease.

For further information please contact:
O.I.C. srl, via Fatebenefratelli no. 19
20121, Milan, Italy
Tel.: +39 02 657-1200; fax: 657-1270
E-mail: internationalconference2004@oic.it

XXX SCANDINAVIAN CONFERENCE OF RHEUMATOLOGY
Göteborg, Sweden, 25-28 August 2004

For further information please contact:
Åsa Eklund, SKD Konferensservice AB
Tel.: +46 (0)46 286-3662; Fax: 286-3666
E-mail: conference@konferens.se
www.konferens.se/rheumatology.2004

XXX SCANDINAVIAN CONFERENCE OF RHEUMATOLOGY
Göteborg, Sweden, 25-28 August 2004

For further information please contact:
Åsa Eklund, SKD Konferensservice AB
Tel.: +46 (0)46 286-3662; Fax: 286-3666
E-mail: conference@konferens.se
www.konferens.se/rheumatology.2004

1ST EUROPEAN COURSE ON CAPILLAROSCOPY AND RHEUMATOID DISEASE
Genoa, Italy, 10-12 September 2004

Purpose: An introductory clinical and practical course on the role of capillaroscopy in Raynaud’s phenomenon and rheumatic diseases.

Scientific secretary: Prof. Maurizio Cutolo, MD, Division of Rheumatology DIMI, University of Genova, Italy. E-mail: mcuto@unige.it

Scientific secretariat: Michela Civellici, EDRA spa, Viale Monza no. 133, 20125 Milan, Italy
Tel.: +39 (02) 281-72300; Fax: 281-72399
E-mail: edracongress@dsmedigroup.com

IV INTERNATIONAL CONFERENCE ON SPONDYLOARTHROPATHIES
Gent, Belgium, 7-9 October 2004

Topics: Inflammatory: Toll-like receptors and chronic inflammation, HSPs as activators of innate immunity, NK receptors and the immune response, gene expression profiles

Genetics and HLA B27: Class II MHC misfolding and inflammation, unusual forms of B27, novel lymphocyte interactions, peptide binding, the human genome scan in AS, genetics of Crohn’s disease

Animal models and pathogenesis: The arthropogenic cell in the B27 transgenic rat, effect of transgenic NK receptors on arthritis, the gut in SpA

Clinical research and therapy: Anti-TNF therapy in SpA.

For further information please contact:
Medicongress, Zaalpoel 28-34, B-9960 Assende, Belgium.
Tel.: +32 (9) 344-3959; fax: 344-4010
E-mail: spondylo@medicongress.com
www.medicongress.com

XI INTERNATIONAL CONFERENCE ON BEHÇET’S DISEASE & III INTERNATIONAL CONVENTION FOR PATIENTS WITH SILK ROAD DISEASE
Antalya, Turkey, 27-31 October 2004

Topics: Genetics, neurologic involvement, outcome measures, guided poster tours, thrombophilia, disease associations, treatment, working group meetings.

Further details are available from:
FIGÜR Congress and Organisation Services
Ayazmaderesi Cad. Karadut sok. No: 7
80888 Dikilitas - Istanbul, Turkey
Tel: 90 (0212) 258 6020; Fax: 90 (0212) 258 6078; E-mail: behcet2004@figur.net
http://www.behcet2004.org
Deadline for the submission of abstracts:
By fax / mail: 15 July 2004
Via internet: 1 August 2004

I V INTERNATIONAL CONGRESS ON AUTOIMMUNITY
Budapest, Hungary, 3-7 November 2004

For further information please contact:
4th International Congress on Autoimmunity
Kenes International Congress Organisers
17 Rue du Cendre, POBox 1726
CH-1211 Geneva 1, Switzerland.
Tel: +41 (22) 908-0488; Fax: 732-2850
autoimm04@kenes.com
www.kenes.com/autoimm04

XI INTERNATIONAL CONFERENCE ON ANTIPHOSPHOLIPID ANTIBODIES
Sydney, Australia, 14-18 November 2004

For complete information on the meeting, please visit the website:http://www.xiphicca2004.unsw.edu.au/sydney/index.html

VI EUROPEAN LUPUS MEETING
Royal College of Physicians, London, UK
3-5 March 2005

Chairman: Professor David Isenberg, MD, FRCP
For further information please contact: Julia Kermode, Conference Organiser at the British Society of Rheumatology.
E-mail: Julia@Rheumatology.org.uk